Eli Samaha Sells 25,027 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

by · The Cerbat Gem

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) major shareholder Eli Samaha sold 25,027 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $17.13, for a total transaction of $428,712.51. Following the completion of the sale, the insider directly owned 9,212,252 shares of the company’s stock, valued at $157,805,876.76. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

  • On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00.
  • On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Performance

Theravance Biopharma stock traded down $0.02 during trading on Wednesday, reaching $16.98. The company had a trading volume of 1,319,960 shares, compared to its average volume of 689,283. Theravance Biopharma, Inc. has a 12-month low of $10.82 and a 12-month high of $21.03. The stock’s 50 day moving average price is $16.56 and its two-hundred day moving average price is $17.29. The firm has a market capitalization of $875.32 million, a price-to-earnings ratio of 7.72 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The company had revenue of $17.70 million for the quarter. As a group, research analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. Creative Planning boosted its holdings in Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 842 shares during the period. State of Wyoming boosted its holdings in Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,019 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 1,020 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. One analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $21.40.

Read Our Latest Report on Theravance Biopharma

Theravance Biopharma Company Profile

(Get Free Report)

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

Read More